echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The national talk is over! Pfizer Paxlovid did not talk about success, and azvudine and lung cleansing detoxification granules entered medical insurance

    The national talk is over! Pfizer Paxlovid did not talk about success, and azvudine and lung cleansing detoxification granules entered medical insurance

    • Last Update: 2023-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    01 Paxlovid was successfully reimbursed until March 31 due to high quotations

    01 Paxlovid was successfully reimbursed until March 31 due to high quotations

    The negotiation of the 2022 national medical insurance drug catalogue officially ended today (January 8), and just now, the National Health Insurance Administration released the participation of new crown treatment drugs in the negotiation of the 2022 medical insurance drug list
    .

    This year, a total of 3 new crown treatment drugs participated in the negotiation, among which, azvudine tablets, lung cleansing and detoxification granules were successfully negotiated, Paxlovid was unsuccessful due to the high quotation of Pfizer Investment Co.
    , Ltd
    .
    , but including Paxlovid, azvudine tablets, monoravir capsules, cold wet granules and other drugs, medical insurance will be temporarily paid until March 31, 2023.

    However, including Paxlovid, drugs such as azvudine tablets, monoravir capsules, and cold wet granules will be temporarily paid by medical insurance until March 31
    , 2023.

    (Taken from the official micro of the National Health Insurance Administration)

    In addition, there are more than 600 kinds of drugs in the national medical insurance drug list to treat fever, cough and other new crown symptoms, and at the same time, the relevant person in charge of the National Medical Insurance Administration said that recently, local medical insurance departments combined with the operation of local medical insurance funds, and temporarily included a batch of new crown symptomatic treatment drugs into the scope of
    medical insurance payment in the region.

    The national medical insurance drug list has more than 600 kinds of drugs for the treatment of fever, cough and other new crown symptoms

    The person in charge also said that the Office of the National Health Insurance Administration recently issued the "Guidelines for the Formation of New Crown Treatment Drugs (Trial)", which adopts full-cycle and multi-level measures to guide enterprises to open, transparent and reasonable pricing
    for newly marketed antiviral therapeutic drugs needed for the prevention and treatment of new coronavirus infection.

    Recently, when it was widely rumored that Pfizer's P drug would drop to 700 yuan / box, a medical representative of Pfizer's P drug promotion said to Cyberblue: "The price will definitely fall, but now we have not notified how much
    to reduce internally.
    " ”

    The price will definitely come down, but we haven't told us how much
    to drop yet.

    02 The number of traditional Chinese medicine enterprises has increased significantly, and some enterprises said, "Talk OK"

    02 The number of traditional Chinese medicine enterprises has increased significantly, and some enterprises said, "Talk OK"

    On the last day of medical insurance negotiations (January 8), the weather was clear, the lowest temperature was -6 °C, and the negotiators of enterprises waiting outside to enter the market were significantly less than in previous days, and at about 8:25, negotiators from major enterprises entered one after another, including Tasly, Simcere, Fangsheng Pharmaceutical, Haosen, etc
    .

    At 9:03 a.
    m.
    , some negotiators walked out of the venue after the first round of quotations to communicate with colleagues on the phone, guessing the quotations of other companies in the same category and discussing their own second round of reduction, etc.
    , and hung up the phone in about 5 minutes and hurriedly returned
    .

    The second day of medical insurance negotiations began non-exclusive bidding, and on the last day, negotiations and bidding began at the same time, and on-site observation found that among the enterprises entering today, there was a significant increase
    in traditional Chinese medicine enterprises.

    At 9:19, the first batch of pharmaceutical companies to complete the negotiations walked out of the venue
    .
    Judging from the time it takes for enterprise negotiators to enter and exit in recent days, the fast talk is generally about 20 minutes
    .

    (January 8, 9:19 a.
    m.
    The first negotiators to walk out of the venue |.
    ) Photo by Cyborg Blue)

    Outside the venue, a number of pharmaceutical companies who came to pick up the negotiators repeatedly tiptoed to look at the venue building, and the staff from two different pharmaceutical companies talked, "There was no movement, not even a personal shadow
    .
    " "It means that the conversation is very intense, and it is falling a dime a dime
    .
    "

    At 9:57, Chia Tai Tianqing walked out of the conference center
    .
    According to the list of varieties that have passed the formal review previously released by the National Medical Insurance Administration, Chia Tai Tianqing Pharmaceutical Group has three products, namely fulvestrant injection, zoledronic acid injection, and anlotinib hydrochloride capsules; Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical has a product, lenalidomide capsules
    .

    At 10:01, the negotiators of Simcere Pharmaceutical walked out of the conference center, and Nanjing Simcere TECO Pharmaceutical has a product that passed the formal review of the National Newspaper Bureau, which is a concentrated solution
    for edaravone dextronicol injection.

    10:34 When asked whether the price reduction was expected, one of the representatives smiled and replied: "The expectation was not met
    .
    " ”

    Hunan Sheng Pharmaceutical has a product that has passed the formal review of the National Medical Insurance Administration, which is a cough granule
    for children's Jingxing.

    It is reported that Hunan Sheng Pharmaceutical's pediatric Jingxing cough granules have been selected into the "Hunan Province New Coronary Pneumonia Traditional Chinese Medicine Prevention and Treatment Plan (2022 Second Edition)"
    .

    A few days ago, the National Health Insurance Administration issued the "2022 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog Adjustment Work Plan", 6 types of drugs are expected to be included, focusing on supporting rare diseases and children's drugs
    .

    In the field of this medical insurance negotiation, it can be seen that there are many pediatric drug companies coming to negotiate, and children's medicine is more likely to face a favorable pattern
    of medical insurance and basic drugs in the future.

    03 A large number of traditional Chinese medicines were negotiated, and the negotiation of lung cleansing and detoxification granules was successful

    03 A large number of traditional Chinese medicines were negotiated, and the negotiation of lung cleansing and detoxification granules was successful

    In recent years, national policies have continuously supported the development of traditional Chinese medicine, the number of new traditional Chinese medicine drugs approved reached a record high in 2021, and the number of traditional Chinese medicines included in medical insurance negotiations has also increased
    significantly.

    Deppon Securities analyzed in a research report that in the list of drugs that passed the formal review published by the National Health Insurance Administration, there were 50 varieties of proprietary Chinese medicines, an increase of 61% year-on-year compared with 31 in 2021, including 15 outside the list, 35 in the catalogue and 4 in traditional Chinese medicine
    injections.
    Except for Yixinone drop pills, the remaining 49 varieties are exclusive varieties
    .
    According to its statistics, among the 50 varieties of Chinese proprietary medicines that passed the formal examination, there were 11 drugs for cold, cough and respiratory diseases, and 8 drugs for cardiovascular and cerebrovascular diseases
    .

    In 2022, the medical insurance catalogue will adjust the off-list proprietary Chinese medicines that have passed the formal review

    In 2022, the medical insurance catalogue will adjust the off-list proprietary Chinese medicines that have passed the formal review

    Screenshot source: Deppon Securities

    In 2022, the medical insurance catalogue will adjust the proprietary Chinese medicines in the catalogue that have passed the formal review

    In 2022, the medical insurance catalogue will adjust the proprietary Chinese medicines in the catalogue that have passed the formal review

    Screenshot source: Deppon Securities

    Medical insurance negotiation is one of the important driving forces for the release of proprietary Chinese medicines, and although the prices of proprietary Chinese medicines included in the medical insurance catalogue every year have decreased, in the game of volume and price, drugs have also enjoyed dividends
    such as hospital admission.

    It is reported that the negotiation approval rates of traditional Chinese medicine medical insurance in 2019 and 2021 were 96% and 84%, respectively, higher than the overall approval rate of 59% and 79%.

    04 Can the general managers of many pharmaceutical companies appear in the "soul bargain"?

    04 Can the general managers of many pharmaceutical companies appear in the "soul bargain"?

    The drugs negotiated this time involve hundreds of clinical drugs such as tumors, rare diseases, and new coronavirus infection, and PD-(L)1 and JW Therapeutics' relkiol-cel are all high-profile large varieties
    .

    On January 7, Min Yin, Chief Commercial Officer of BeiGene Greater China, Xiaobin Wu, President, COO and General Manager of BeiGene China, and Oslang, Global Vice President and General Manager of AbbVie China, attended the event
    .

    PD-(L)1 has long been a major focus
    of annual health care negotiations.
    CITIC Securities analyzed in a research report that all three imported drugs (pembrolizumab, nivolumab and durvalumab) in 2021 had lower declines in negotiations, presumably due to global pricing strategies
    .

    Domestic PD-1 "four tigers" have all new indications, of which tislelizumab has 4 new indications
    .
    Cinda, Hengrui and Junshi have all passed first-line esophageal cancer trials, and the competition is very fierce
    .

    BeiGene said in its third-quarter 2022 earnings report that sales growth was driven by new approved indications driving market penetration and market share, while the expansion of reimbursement in the medical insurance catalogue brought more new patient demand
    .

    PD-(L)1 entered the medical insurance catalog, and the benefits brought by the increase are self-evident
    .
    At present, the market size of PD-(L)1 is still considerable
    .
    According to Sullivan, the global PD-(L)1 market is expected to reach $62.
    6 billion by 2025.

    Among them, China's PD-(L)1 market size is expected to reach 51.
    9 billion yuan in 2025.

    "Every small group should not be abandoned" "I feel like the tears I just had just now are about to fall".
    .
    .
    The picture of "soul bargaining" in 2021 is vividly remembered, and the purchase price of the CAR-T product Rucki Orencel that passed the formal review this year is 1.
    29 million yuan / needle, which is 90,000 yuan more expensive than the unselected Aquilencel injection, and in this year's medical insurance negotiation field, the appearance of JW Therapeutics
    ' negotiators has not been clearly seen.
    Whether the "soul bargain" can be reproduced this year, the specific results will have to wait for the official notice
    .

    At present, the total number of drugs in the national medical insurance drug list has reached 2860, including 1486 Western medicines and 1374 Chinese
    patent medicines.
    There are 892 kinds of
    Chinese medicine pieces.

    The National Health Insurance Administration clarified that the agreement will be negotiated in the catalogue that expires on December 31, 2022, and the validity period of the original agreement will be automatically extended to the official implementation
    of the new version of the catalogue.

    After nearly 4 days of negotiation and bidding, which varieties have entered the latest version of the medical insurance catalog, Cyborn Blue will continue to pay attention
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.